Muscle dysfunction in cancer patients

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 947-958

  Christensen, J F ^a,b   Jones, L W ^c   Andersen, J L ^d,e   Daugaard, G ^b   Rorth, M ^b   Hojman, P ^b  

^a The University Hospitals Centre for Health Care Research

^b Mental Health Services CPH   (Denmark)

^c DUKE CANCER INSTITUTE   (United States)

^d BISPEBJERG HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cancer; exercise; muscle mass; muscle strength; skeletal muscle

Indexed keywords

ANIMAL; HUMAN; KINESIOTHERAPY; MORTALITY; MUSCLE STRENGTH; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; SKELETAL MUSCLE; TREATMENT OUTCOME;

ANIMALS; EXERCISE THERAPY; HUMANS; MUSCLE STRENGTH; MUSCLE, SKELETAL; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84904133317     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt551     Document Type: Review

References (85)

1. Ehrenborg, E., Krook, A., Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol Rev 61 (2009), 373–393.
2. Pedersen, B.K., Exercise-induced myokines and their role in chronic diseases. Brain Behav Immun 25 (2011), 811–816.
3. Ruiz, J.R., Sui, X., Lobelo, F., et al. Association between muscular strength and mortality in men: prospective cohort study. BMJ, 337, 2008, a439.
4. Argiles, J.M., Busquets, S., Toledo, M., et al. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3 (2009), 263–268.
5. Argiles, J.M., Cancer-associated malnutrition. Eur J Oncol Nurs 9:Suppl 2 (2005), S39–S50.
6. Tisdale, M.J., Mechanisms of cancer cachexia. Physiol Rev 89 (2009), 381–410.
7. Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39 (2010), 412–423.
8. Prado, C.M., Lieffers, J.R., McCargar, L.J., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9 (2008), 629–635.
9. Martin, L., Birdsell, L., MacDonald, N., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31 (2013), 1539–1547.
10. Tan, B.H., Birdsell, L.A., Martin, L., et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15 (2009), 6973–6979.
11. van Vledder, M.G., Levolger, S., Ayez, N., et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99 (2012), 550–557.
12. Villasenor, A., Ballard-Barbash, R., Baumgartner, K., et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6 (2012), 398–406.
13. Wojtaszewski, J.F., Nielsen, J.N., Richter, E.A., Invited review: effect of acute exercise on insulin signaling and action in humans. J Appl Physiol 93 (2002), 384–392.
14. Burden, S.T., Hill, J., Shaffer, J.L., et al. Nutritional status of preoperative colorectal cancer patients. J Hum Nutr Diet 23 (2010), 402–407.
15. Soyupek, F., Soyupek, S., Perk, H., et al. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol 26 (2008), 141–146.
16. Harrington, S., Padua, D., Battaglini, C., et al. Comparison of shoulder flexibility, strength, and function between breast cancer survivors and healthy participants. J Cancer Surviv 5 (2011), 167–174.
17. Ness, K.K., Jones, K.E., Smith, W.A., et al. Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil 94 (2013), 1451–1457.
18. Cao, D.X., Wu, G.H., Zhang, B., et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr 29 (2010), 72–77.
19. Freedman, R.J., Aziz, N., Albanes, D., et al. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab 89 (2004), 2248–2253.
20. Greenspan, S.L., Coates, P., Sereika, S.M., et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90 (2005), 6410–6417.
21. Reis, C., Liberman, S., Pompeo, A.C., et al. Body composition alterarions, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics (Sao Paulo) 64 (2009), 781–784.
22. Awad, S., Tan, B.H., Cui, H., et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31 (2012), 74–77.
23. Bossola, M., Muscaritoli, M., Costelli, P., et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 280 (2001), R1518–R1523.
24. Smith, I.J., Aversa, Z., Hasselgren, P.O., et al. Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. Muscle Nerve 43 (2011), 410–414.
25. Aversa, Z., Bonetto, A., Penna, F., et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 19 (2012), 1350–1356.
26. Weber, M.A., Kinscherf, R., Krakowski-Roosen, H., et al. Myoglobin plasma level related to muscle mass and fiber composition: a clinical marker of muscle wasting?. J Mol Med 85 (2007), 887–896.
27. Yancik, R., Population aging and cancer: a cross-national concern. Cancer J 11 (2005), 437–441.
28. Janssen, I., Heymsfield, S.B., Wang, Z.M., et al. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. J Appl Physiol 89 (2000), 81–88.
29. Andersen, J.L., Muscle fibre type adaptation in the elderly human muscle. Scand J Med Sci Sports 13 (2003), 40–47.
30. Roos, M.R., Rice, C.L., Vandervoort, A.A., Age-related changes in motor unit function. Muscle Nerve 20 (1997), 679–690.
31. Extermann, M., Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35 (2000), 181–200.
32. Bozzetti, F., Mariani, L., Lo, V.S., et al. The nutritional risk in oncology: a study of 1,453 cancer outpatients. Support Care Cancer 20 (2012), 1919–1928.
33. Wolfe, R.R., The underappreciated role of muscle in health and disease. Am J Clin Nutr 84 (2006), 475–482.
34. Kortebein, P., Ferrando, A., Lombeida, J., et al. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA 297 (2007), 1772–1774.
35. Ferriolli, E., Skipworth, R.J., Hendry, P., et al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy?. J Pain Symptom Manage 43 (2012), 1025–1035.
36. Demark-Wahnefried, W., Peterson, B.L., Winer, E.P., et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19 (2001), 2381–2389.
37. Sakuma, K., Yamaguchi, A., Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 3 (2012), 77–94.
38. Fearon, K.C., Cancer cachexia and fat-muscle physiology. N Engl J Med 365 (2011), 565–567.
39. Tisdale, M.J., Are tumoral factors responsible for host tissue wasting in cancer cachexia?. Future Oncol 6 (2010), 503–513.
40. Temparis, S., Asensi, M., Taillandier, D., et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 54 (1994), 5568–5573.
41. Khal, J., Wyke, S.M., Russell, S.T., et al. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer 93 (2005), 774–780.
42. Bossola, M., Muscaritoli, M., Costelli, P., et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237 (2003), 384–389.
43. Zampieri, S., Doria, A., Adami, N., et al. Subclinical myopathy in patients affected with newly diagnosed colorectal cancer at clinical onset of disease: evidence from skeletal muscle biopsies. Neurol Res 32 (2010), 20–25.
44. Koppenol, W.H., Bounds, P.L., Dang, C.V., Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11 (2011), 325–337.
45. Qing, G., Li, B., Vu, A., et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22 (2012), 631–644.
46. Chen, Y., Jungsuwadee, P., Vore, M., et al. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 7 (2007), 147–156.
47. Blomqvist, L., Stark, B., Engler, N., et al. Evaluation of arm and shoulder mobility and strength after modified radical mastectomy and radiotherapy. Acta Oncol 43 (2004), 280–283.
48. Hamilton, E.J., Gianatti, E., Strauss, B.J., et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 74 (2011), 377–383.
49. Poterucha, T., Burnette, B., Jatoi, A., A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med Oncol 29 (2012), 1005–1009.
50. Bonifati, D.M., Ori, C., Rossi, C.R., et al. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol 46 (2000), 517–522.
51. van, N.K., van, H.A., Argiles, J.M., et al. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer 100 (2009), 311–314.
52. Short, K.R., Bigelow, M.L., Nair, K.S., Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab 297 (2009), E1260–E1268.
53. Khaleeli, A.A., Edwards, R.H., Gohil, K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 18 (1983), 155–166.
54. Sayer, A.A., Dennison, E.M., Syddall, H.E., et al. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg?. Diabetes Care 28 (2005), 2541–2542.
55. Samuel, D., Rowe, P., Hood, V., et al. The relationships between muscle strength, biomechanical functional moments and health-related quality of life in non-elite older adults. Age Ageing 41 (2012), 224–230.
56. Sabel, M.S., Lee, J., Cai, S., et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18 (2011), 3579–3585.
57. Prado, C.M., Baracos, V.E., McCargar, L.J., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15 (2009), 2920–2926.
58. Antoun, S., Baracos, V.E., Birdsell, L., et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21 (2010), 1594–1598.
59. Prado, C.M., Baracos, V.E., McCargar, L.J., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13 (2007), 3264–3268.
60. Peng, P.D., van Vledder, M.G., Tsai, S., et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 13 (2011), 439–446.
61. Chen, C.H., Ho, C., Huang, Y.Z., et al. Hand-grip strength is a simple and effective outcome predictor in esophageal cancer following esophagectomy with reconstruction: a prospective study. J Cardiothorac Surg, 6, 2011, 98.
62. Jones, L.W., Friedman, A.H., West, M.J., et al. Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer 116 (2010), 695–704.
63. Cantarero-Villanueva, I., Fernandez-Lao, C., az-Rodriguez, L., et al. The handgrip strength test as a measure of function in breast cancer survivors: relationship to cancer-related symptoms and physical and physiologic parameters. Am J Phys Med Rehabil 91 (2012), 774–782.
64. Kilgour, R.D., Vigano, A., Trutschnigg, B., et al. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 1 (2010), 177–185.
65. Lavie, C.J., Thomas, R.J., Squires, R.W., et al. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 84 (2009), 373–383.
66. Puhan, M.A., Schunemann, H.J., Frey, M., et al. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax 60 (2005), 367–375.
67. Lakoski, S.G., Eves, N.D., Douglas, P.S., et al. Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 9 (2012), 288–296.
68. Egan, B., Zierath, J.R., Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 17 (2013), 162–184.
69. Wernbom, M., Augustsson, J., Thomee, R., The influence of frequency, intensity, volume and mode of strength training on whole muscle cross-sectional area in humans. Sports Med 37 (2007), 225–264.
70. Jones, L.W., Peppercorn, J., Exercise research: early promise warrants further investment. Lancet Oncol 11 (2010), 408–410.
71. Mishra, S.I., Scherer, R.W., Geigle, P.M., et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev, 8, 2012, CD007566.
72. Schmitz, K.H., Courneya, K.S., Matthews, C., et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42 (2010), 1409–1426.
73. Strasser, B., Steindorf, K., Wiskemann, J., et al. Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc 45 (2013), 2080–2090.
74. Segal, R.J., Reid, R.D., Courneya, K.S., et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27 (2009), 344–351.
75. Courneya, K.S., Segal, R.J., Mackey, J.R., et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25 (2007), 4396–4404.
76. Oldervoll, L.M., Loge, J.H., Lydersen, S., et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 16 (2011), 1649–1657.
77. Quist, M., Rorth, M., Langer, S., et al. Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study. Lung Cancer 75 (2012), 203–208.
78. Hanson, E.D., Sheaff, A.K., Sood, S., et al. Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy. J Gerontol A Biol Sci Med Sci 68 (2012), 490–498.
79. LaStayo, P.C., Marcus, R.L., Dibble, L.E., et al. Eccentric exercise versus usual-care with older cancer survivors: the impact on muscle and mobility–an exploratory pilot study. BMC Geriatr, 11, 2011, 5.
80. Christensen, J.F., Andersen, J.L., Adamsen, L., et al. Progressive resistance training and cancer testis (PROTRACT)—efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial. BMC Cancer, 11, 2011, 326.
81. Thorsen, L., Nilsen, T.S., Raastad, T., et al. A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design. BMC Cancer, 12, 2012, 123.
82. Jones, L.W., Eves, N.D., Kraus, W.E., et al. The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer, 10, 2010, 155.
83. Jones, L.W., Douglas, P.S., Eves, N.D., et al. Rationale and design of the Exercise Intensity Trial (EXCITE): a randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. BMC Cancer, 10, 2010, 531.
84. Jones, L.W., Eves, N.D., Haykowsky, M., et al. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 10 (2009), 598–605.
85. Koelwyn, G.J., Khouri, M., Mackey, J.R., et al. Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol 30 (2012), 4458–4461.